ACET - CIK 0001720580
Adicet Bio, Inc. trades as ACET. This page tracks Adicet Bio, Inc. through 658 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Annual report (amended) | 10-K/A | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| S-8 POS | - | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
The largest companies sharing Adicet Bio, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Adicet Bio, Inc. reported a net loss of $116.80M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.